Myriad Genetics, Inc (NASDAQ: MYGN) on Friday, soared 1.44% from the previous trading day, before settling in for the closing price of $13.17. Within the past 52 weeks, MYGN’s price has moved between $12.87 and $29.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 4.63%. The company achieved an average annual earnings per share of 147.30%. With a float of $87.62 million, this company’s outstanding shares have now reached $91.00 million.
Considering the fact that the conglomerate employs 2700 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 69.15%, operating margin of -14.06%, and the pretax margin is -14.16%.
Myriad Genetics, Inc (MYGN) Insider Activity
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Myriad Genetics, Inc is 3.75%, while institutional ownership is 100.22%. The most recent insider transaction that took place on Oct 11 ’24, was worth 343,950. In this transaction President and CEO of this company sold 15,000 shares at a rate of $22.93, taking the stock ownership to the 962,378 shares. Before that another transaction happened on Oct 11 ’24, when Company’s Officer proposed sale 15,000 for $22.93, making the entire transaction worth $343,950.
Myriad Genetics, Inc (MYGN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 147.30% per share during the next fiscal year.
Myriad Genetics, Inc (NASDAQ: MYGN) Trading Performance Indicators
Myriad Genetics, Inc (MYGN) is currently performing well based on its current performance indicators. A quick ratio of 1.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.30, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Myriad Genetics, Inc (MYGN)
Compared to the last year’s volume of 0.77 million, its volume of 1.48 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 11.21%. Additionally, its Average True Range was 0.82.
During the past 100 days, Myriad Genetics, Inc’s (MYGN) raw stochastic average was set at 2.98%, which indicates a significant decrease from 12.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.05% in the past 14 days, which was lower than the 51.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.86, while its 200-day Moving Average is $22.71. Nevertheless, the first resistance level for the watch stands at $13.60 in the near term. At $13.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $14.12. If the price goes on to break the first support level at $13.08, it is likely to go to the next support level at $12.80. Should the price break the second support level, the third support level stands at $12.56.
Myriad Genetics, Inc (NASDAQ: MYGN) Key Stats
Market capitalization of the company is 1.23 billion based on 91,035K outstanding shares. Right now, sales total 753,200 K and income totals -263,300 K. The company made 213,300 K in profit during its latest quarter, and -22,100 K in sales during its previous quarter.
